Importantly, we also show that FGFR2 loss can fully prevent the development of Wnt/βCat–driven adrenal hyperplasia and that FGFR inhibitors can decrease aldosterone secretion. This evidence concerns the gene FGFR2 and congenital adrenal hyperplasia.